Ceftibuten

IUPAC: ( ) - ( 6R, 7R) -7 - [ (Z) -2 - (2- aminothiazol-4 -yl ) - 4 - carboxycrotonamido ] -8 -oxo- 5 -thia -1 -azabicyclo [4.2. 0] oct-2 -ene-2 ​​-carboxylic acid

J01DD14

β -lactam antibiotics ( Cephalosporin 3rd generation)

Template: Infobox chemical / molecular formula search available

Ceftibuten is a drug from the group of third generation cephalosporins, which are among the β -lactam antibiotics. It is used to treat bronchitis, sinusitis ( sinus infection ) and infection of the kidney, the tonsils, the throat and the middle ear are used. It also finds use as oral continuation therapy when intravenous cephalosporins are no longer necessary for continued treatment. Ceftibuten was patented in 1985 by Shionogi, used the dihydrate.

Spectrum of activity

Not effective against Staphylococcus aureus. Only partly effective against pneumococcus (Streptococcus pneumoniae) and group B streptococci (Streptococcus agalactiae ). Effective against Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and other Enterobacteriaceae. Of advantage are the prolonged half-life and high β - Laktamasestabilität.

Application

Ceftibuten is administered orally as the dihydrate.

Side effects

Gastrointestinal symptoms are the most common side effects that may occur while taking ceftibuten. In addition, it can also lead to vomiting and diarrhea.